Most Read Articles
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
4 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.
2 days ago
Adolescents who sleep longer and have higher sleep efficiency have a favourable cardiometabolic profile, including lower abdominal adiposity, lower systolic blood pressure and higher high-density lipoprotein cholesterol levels, as shown in a study.

Low-dose bevacizumab effective for treating retinopathy of prematurity

09 Jul 2018

Low-dose bevacizumab yields excellent retinal structural outcomes in the treatment of retinopathy of prematurity (ROP), although a number of infants may still require additional treatment, as shown in a study.

A total of 61 premature infants with type 1 ROP received bevacizumab intravitreal injections at de-escalating doses of 0.25, 0.125, 0.063 or 0.031 mg in the study eye. If needed, fellow eyes received treatment at one-dose level higher: 0.625, 0.25, 0.125 or 0.063 mg, respectively. Additional treatment was or was not given after 4 weeks.

The main outcomes investigated were early and late ROP recurrences, additional treatments, and structural outcomes after 6 months.

Additional treatment was administered to 25 of 61 study eyes (41 percent) due to early treatment failure (within 4 weeks; n=3), late recurrence of ROP (after 4 weeks; n=11) or persistent avascular retina (n=11).

Specifically, retreatment for early failure or late recurrence occurred in two of 11 eyes (18 percent) given 0.25 mg, four of 16 eyes (25 percent) given 0.125 mg, eight of 24 eyes (33 percent) given 0.063 mg and none of 10 eyes (0 percent) given 0.031 mg.

By 6 months corrected age, 56 infants had ROP regression with normal posterior poles, one developed a stage 5 retinal detachment, and four had died of pre-existing medical conditions.

Further investigations are being conducted to test lower doses of bevacizumab, which may lead to enhanced normal retinal vascularization while posing lower systemic risk, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
4 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.
2 days ago
Adolescents who sleep longer and have higher sleep efficiency have a favourable cardiometabolic profile, including lower abdominal adiposity, lower systolic blood pressure and higher high-density lipoprotein cholesterol levels, as shown in a study.